Loading...

An Open-label, Randomized, 2-Period Crossover Study to Determine the Bioequivalency of the Phase 3 SYR-322 Tablets (12.5 and 25 mg) With the Commercial SYR-322 Tablets (12.5 and 25 mg) in Healthy Adult Subjects - Vivli | NLM Dataset Catalog